Most American investors are familiar with large European drug companies like Sanofi and Novartis (NYSE:NVS), but the mid-cap drugmakers like Ipsen (OTCPK:IPSEY) don't get as much attention. That's unfortunate, as Ipsen is one of several high-quality smaller European pharmaceutical companies.
Ipsen shares don't look significantly underpriced today, but there could some developments that could drive shares higher. Phase III data on tasquinimod could make this drug a viable alternative in the crowded prostate cancer space, and Ipsen may be on the prowl for licensing or acquisition opportunities to take advantage of a new U.S. oncology sales infrastructure. I'd more interested in these shares closer to EUR 30, but they look like a decent enough hold at...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|